It’s been a mixed week for Pfizer. First, Pfizer/Pharmacia settled with the Department of Justice (DoJ) for $34.7 million to resolve matters related to off-label promotion of Genotropin.
And in the win column, the U.S. Supreme Court rejected an appeal by Ranbaxy Laboratories in its now failed bid to challenge Pfizer’s patent on Lipitor.
Still too soon to say if the tides are turning...
